Clinical study of hematopoietic stem cell transplantation combined with post-cyclophosphamide regimen in the treatment of transfusion-dependent thalassemia

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200064820

Enrollment

Unknown

Registered

2022-10-19

Start date

2022-10-20

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention Group:Thalassemia transplantation pretreatment scheme Bu+Cy+Flu and GVHD prevention and treatment scheme MTX+CSA plus PYCy scheme

Eligibility

Sex/Gender

All

Age

1 Years to 15 Years

Inclusion criteria

Inclusion criteria: 1. Transfusion-dependent thalassemia patients have been diagnosed. 2. Successful HLA matching and aged range from 1 to 15 years. 3. No other immunosuppressants were taken before the experiment. 4. Patient compliance was good. Legal guardian agreed to participate in the experiment and signed the informed consent.

Exclusion criteria

Exclusion criteria: Patients with severe liver, kidney or heart dysfunction are not suitable to participate in treatment.

Design outcomes

Primary

Measure	Time frame
Implant rate;Routine blood test;GVHD-free and relapse-free survival (GRFS);Complication free survival (CFS);	—

Secondary

Measure	Time frame
Overall survival (OS);	—

Countries

China

Contacts

Public ContactHe Yunyan

Key Laboratory of National Health Commission, the First Affiliated Hospital of Guangxi Medical University

yunyanhe@aliyun.com+86 13607868275

Outcome results